NASDAQ:ACET

Adicet Bio Stock News

Healthcare > Biotechnology

Buy ACET

*Your capital is at risk

$9.11

+0.0500 (+0.552%)

At Close: Jul 31, 2026

Adicet Bio Receives FDA Fast Track Designation for ADI-001 for the Treatment of Refractory Systemic Lupus Erythematosus (SLE) with Extrarenal Involvement

07:10am, Wednesday, 05'th Feb 2025

REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmun

Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

06:06pm, Friday, 31'st Jan 2025

Adicet Bio to Participate in a Fireside Chat at the Guggenheim Securities SMID Cap Biotech Conference

07:00am, Wednesday, 29'th Jan 2025

Adicet Bio Provides Corporate Update and Highlights Expected 2025 Milestones

04:10pm, Wednesday, 08'th Jan 2025

Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

04:48pm, Tuesday, 31'st Dec 2024

Adicet Bio Announces First Patient Dosed in the Phase 1 Clinical Trial of ADI-270 in Metastatic/Advanced Clear Cell Renal Cell Carcinoma

07:00am, Thursday, 19'th Dec 2024

Adicet Bio Appoints Julie Maltzman, M.D. as Chief Medical Officer

07:00am, Wednesday, 18'th Dec 2024

Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

04:44pm, Friday, 29'th Nov 2024

Adicet Opens Enrollment for ADI-270 Phase 1 Clinical Trial in Metastatic/Advanced Clear Cell Renal Cell Carcinoma

04:00pm, Monday, 18'th Nov 2024

Adicet Bio Presents Clinical Biomarker Data for Off-the-Shelf CAR T Cell Therapy in an Oral Session at the American College of Rheumatology (ACR) Convergence 2024

09:00am, Saturday, 16'th Nov 2024

REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic, gamma delta T cell therapies for autoimmu

Adicet Bio to Participate in Upcoming Investor Conferences

07:00am, Friday, 01'st Nov 2024

Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

05:31pm, Thursday, 31'st Oct 2024

Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

05:08pm, Monday, 30'th Sep 2024

Adicet Bio to Present at the American Society of Gene & Cell Therapy's (ASGCT) 2024 Advancing Gene + Cell Therapies for Cancer Conference

04:30pm, Monday, 30'th Sep 2024

Adicet Opens Enrollment for ADI-001 Phase 1 Clinical Trial in Autoimmune Diseases

07:00am, Monday, 30'th Sep 2024

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by